Boditech Med Executive and Leadership Team

Yule Choi, the Chief Executive Officer at Boditech Med, directs the company's strategic vision and operational execution. This leadership role involves guiding Boditech Med's mission to improve global health through innovative in-vitro diagnostic solutions. Overseeing the development and deployment of 85 biomarkers, Choi ensures the company meets evolving customer needs across capillary blood, venous blood, and plasma testing. The Chief Executive Officer's focus extends to expanding Boditech Med's reach in 120 countries, solidifying its position as a global leader in point-of-care testing. Yule Choi drives the company's commitment to enhancing quality of life by making advanced diagnostic tools accessible worldwide. This executive's leadership ensures continued growth and market penetration in the competitive diagnostics sector.

Euiyul Choi, the Founder & Chief Executive Officer at Boditech Med, establishes the foundational principles and long-term direction for the company's innovative in-vitro diagnostic solutions. As Founder, Choi imbues the organization with a legacy of improving health and quality of life, a mission central to Boditech Med's operations since its 1998 inception. The Chief Executive Officer role encompasses strategic oversight of the development of 85 biomarkers, supporting diverse testing needs from capillary blood to plasma. Euiyul Choi guides the company's expansion into 120 countries, reinforcing its global leadership in point-of-care testing. This executive's vision propels Boditech Med's commitment to advancing healthcare accessibility and efficacy worldwide. The Founder & Chief Executive Officer ensures sustained innovation and market leadership.

Eui-Yul Choi, the Co-Founder & Chief Executive Officer at Boditech Med, spearheads the company's strategic initiatives and global market presence. This leadership position involves driving the innovation pipeline for in-vitro diagnostic solutions that enhance health and quality of life. As Co-Founder, Eui-Yul Choi cultivates a culture of continuous improvement, essential for developing the 85 biomarkers Boditech Med offers for capillary, venous, and plasma testing. The Chief Executive Officer oversees the company's extensive network, serving patients and clinicians in 120 countries. Eui-Yul Choi's strategic direction ensures Boditech Med maintains its status as a global leader in point-of-care diagnostics. This executive's commitment to technological advancement fuels the company's mission to provide accessible, high-quality healthcare solutions worldwide.

Keith Nahm, the Chief Technology Officer at Boditech Med, architects the technological roadmap and drives innovation in diagnostic solutions. This critical role involves overseeing the research and development of Boditech Med's extensive portfolio of 85 biomarkers, ensuring cutting-edge capabilities for capillary, venous blood, and plasma testing. The Chief Technology Officer leads efforts to enhance the performance and reliability of in-vitro diagnostic tools, directly supporting the company's mission to improve global health outcomes. Keith Nahm's technical leadership is instrumental in maintaining Boditech Med's competitive edge and expanding its product offerings to meet the evolving demands of clinicians and patients across 120 countries. This executive ensures technological advancements align with the company's strategic goals for point-of-care testing leadership.